Zimmer Biomet Holdings, Inc. (NYSE: ZBH) Stock Competitors & Peer Comparison

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while BSX-PA trades at $122.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, ZBH's ROE is +0.06%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, ZBH is less volatile compared to BSX-PA. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check BSX-PA's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, ABT has a market cap of 175.3B. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while ABT trades at $101.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas ABT's P/E ratio is 19.44. In terms of profitability, ZBH's ROE is +0.06%, compared to ABT's ROE of +0.11%. Regarding short-term risk, ZBH is more volatile compared to ABT. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check ABT's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, MDT has a market cap of 113.5B. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while MDT trades at $88.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas MDT's P/E ratio is 16.03. In terms of profitability, ZBH's ROE is +0.06%, compared to MDT's ROE of +0.11%. Regarding short-term risk, ZBH is more volatile compared to MDT. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check MDT's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, SYK has a market cap of 104.5B. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while SYK trades at $272.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas SYK's P/E ratio is 20.35. In terms of profitability, ZBH's ROE is +0.06%, compared to SYK's ROE of +0.16%. Regarding short-term risk, ZBH is more volatile compared to SYK. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check SYK's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, BSX has a market cap of 65.3B. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while BSX trades at $43.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas BSX's P/E ratio is 14.17. In terms of profitability, ZBH's ROE is +0.06%, compared to BSX's ROE of +0.15%. Regarding short-term risk, ZBH is less volatile compared to BSX. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check BSX's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, EW has a market cap of 49.7B. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while EW trades at $86.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas EW's P/E ratio is 31.96. In terms of profitability, ZBH's ROE is +0.06%, compared to EW's ROE of +0.10%. Regarding short-term risk, ZBH is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check EW's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, DXCM has a market cap of 32.7B. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while DXCM trades at $86.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas DXCM's P/E ratio is 33.97. In terms of profitability, ZBH's ROE is +0.06%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, ZBH is more volatile compared to DXCM. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check DXCM's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, GEHC has a market cap of 30.1B. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while GEHC trades at $66.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas GEHC's P/E ratio is 14.61. In terms of profitability, ZBH's ROE is +0.06%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, ZBH is more volatile compared to GEHC. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check GEHC's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, PHG has a market cap of 24.4B. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while PHG trades at $24.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas PHG's P/E ratio is 14.26. In terms of profitability, ZBH's ROE is +0.06%, compared to PHG's ROE of +0.10%. Regarding short-term risk, ZBH is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check PHG's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while ABMD trades at $381.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas ABMD's P/E ratio is 65.36. In terms of profitability, ZBH's ROE is +0.06%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, ZBH is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check ABMD's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while SWAV trades at $334.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas SWAV's P/E ratio is 78.76. In terms of profitability, ZBH's ROE is +0.06%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, ZBH is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check SWAV's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, PEN has a market cap of 12.6B. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while PEN trades at $318.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas PEN's P/E ratio is 83.25. In terms of profitability, ZBH's ROE is +0.06%, compared to PEN's ROE of +0.11%. Regarding short-term risk, ZBH is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check PEN's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, SNN has a market cap of 11.3B. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while SNN trades at $26.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas SNN's P/E ratio is 18.17. In terms of profitability, ZBH's ROE is +0.06%, compared to SNN's ROE of +0.12%. Regarding short-term risk, ZBH is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check SNN's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, BIO-B has a market cap of 10.5B. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while BIO-B trades at $385.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas BIO-B's P/E ratio is -67.89. In terms of profitability, ZBH's ROE is +0.06%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, ZBH is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check BIO-B's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, ALGN has a market cap of 10.5B. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while ALGN trades at $146.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas ALGN's P/E ratio is 13.38. In terms of profitability, ZBH's ROE is +0.06%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, ZBH is more volatile compared to ALGN. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check ALGN's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, BIO has a market cap of 10.3B. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while BIO trades at $381.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas BIO's P/E ratio is 41.05. In terms of profitability, ZBH's ROE is +0.06%, compared to BIO's ROE of +0.03%. Regarding short-term risk, ZBH is more volatile compared to BIO. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check BIO's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, GMED has a market cap of 10.1B. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while GMED trades at $74.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas GMED's P/E ratio is 16.79. In terms of profitability, ZBH's ROE is +0.06%, compared to GMED's ROE of +0.12%. Regarding short-term risk, ZBH is more volatile compared to GMED. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check GMED's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, BRKR has a market cap of 9.8B. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while BRKR trades at $64.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas BRKR's P/E ratio is 32.25. In terms of profitability, ZBH's ROE is +0.06%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, ZBH is less volatile compared to BRKR. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check BRKR's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, BRKRP has a market cap of 9.4B. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while BRKRP trades at $470.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas BRKRP's P/E ratio is 255.66. In terms of profitability, ZBH's ROE is +0.06%, compared to BRKRP's ROE of -0.03%. Regarding short-term risk, ZBH is more volatile compared to BRKRP. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check BRKRP's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, PODD has a market cap of 9.4B. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while PODD trades at $136.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas PODD's P/E ratio is 23.19. In terms of profitability, ZBH's ROE is +0.06%, compared to PODD's ROE of +0.27%. Regarding short-term risk, ZBH is more volatile compared to PODD. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check PODD's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while MASI trades at $179.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas MASI's P/E ratio is 44.43. In terms of profitability, ZBH's ROE is +0.06%, compared to MASI's ROE of +0.09%. Regarding short-term risk, ZBH is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check MASI's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, GKOS has a market cap of 9.1B. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while GKOS trades at $154.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas GKOS's P/E ratio is -180.02. In terms of profitability, ZBH's ROE is +0.06%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, ZBH is less volatile compared to GKOS. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check GKOS's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, HAE has a market cap of 4.8B. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while HAE trades at $105.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas HAE's P/E ratio is 21.02. In terms of profitability, ZBH's ROE is +0.06%, compared to HAE's ROE of +0.11%. Regarding short-term risk, ZBH is more volatile compared to HAE. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check HAE's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while NARI trades at $79.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas NARI's P/E ratio is -59.24. In terms of profitability, ZBH's ROE is +0.06%, compared to NARI's ROE of -0.00%. Regarding short-term risk, ZBH is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check NARI's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while ITGR trades at $126.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas ITGR's P/E ratio is 19.89. In terms of profitability, ZBH's ROE is +0.06%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, ZBH is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check ITGR's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, LIVN has a market cap of 4.2B. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while LIVN trades at $76.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas LIVN's P/E ratio is 18.20. In terms of profitability, ZBH's ROE is +0.06%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, ZBH is less volatile compared to LIVN. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check LIVN's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while AXNX trades at $70.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas AXNX's P/E ratio is -709.80. In terms of profitability, ZBH's ROE is +0.06%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, ZBH is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check AXNX's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, IRTC has a market cap of 3.6B. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while IRTC trades at $110.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas IRTC's P/E ratio is -256.70. In terms of profitability, ZBH's ROE is +0.06%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, ZBH is more volatile compared to IRTC. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check IRTC's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, NEOG has a market cap of 3B. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while NEOG trades at $13.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas NEOG's P/E ratio is 49.14. In terms of profitability, ZBH's ROE is +0.06%, compared to NEOG's ROE of -0.00%. Regarding short-term risk, ZBH is less volatile compared to NEOG. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check NEOG's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, TMDX has a market cap of 2.9B. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while TMDX trades at $85.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas TMDX's P/E ratio is 43.29. In terms of profitability, ZBH's ROE is +0.06%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, ZBH is less volatile compared to TMDX. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check TMDX's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, BFLY has a market cap of 2.5B. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while BFLY trades at $9.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas BFLY's P/E ratio is -39.13. In terms of profitability, ZBH's ROE is +0.06%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, ZBH is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check BFLY's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, AXGN has a market cap of 2.3B. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while AXGN trades at $43.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas AXGN's P/E ratio is 114.18. In terms of profitability, ZBH's ROE is +0.06%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, ZBH is less volatile compared to AXGN. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check AXGN's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, UFPT has a market cap of 2.3B. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while UFPT trades at $295.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas UFPT's P/E ratio is 30.20. In terms of profitability, ZBH's ROE is +0.06%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, ZBH is more volatile compared to UFPT. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check UFPT's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while NUVA trades at $39.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas NUVA's P/E ratio is 75.00. In terms of profitability, ZBH's ROE is +0.06%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, ZBH is less volatile compared to NUVA. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check NUVA's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, INSP has a market cap of 2B. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while INSP trades at $70.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas INSP's P/E ratio is 31.06. In terms of profitability, ZBH's ROE is +0.06%, compared to INSP's ROE of +0.18%. Regarding short-term risk, ZBH is less volatile compared to INSP. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check INSP's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, ESTA has a market cap of 1.9B. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while ESTA trades at $65.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas ESTA's P/E ratio is -52.36. In terms of profitability, ZBH's ROE is +0.06%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, ZBH is less volatile compared to ESTA. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check ESTA's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, NVCR has a market cap of 1.8B. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while NVCR trades at $15.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas NVCR's P/E ratio is -12.18. In terms of profitability, ZBH's ROE is +0.06%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, ZBH is more volatile compared to NVCR. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check NVCR's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, ATEC has a market cap of 1.6B. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while ATEC trades at $10.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas ATEC's P/E ratio is -168.67. In terms of profitability, ZBH's ROE is +0.06%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, ZBH is less volatile compared to ATEC. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check ATEC's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, CNMD has a market cap of 1.4B. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while CNMD trades at $45.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas CNMD's P/E ratio is 9.97. In terms of profitability, ZBH's ROE is +0.06%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, ZBH is less volatile compared to CNMD. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check CNMD's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while HSKA trades at $119.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas HSKA's P/E ratio is -62.49. In terms of profitability, ZBH's ROE is +0.06%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, ZBH is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check HSKA's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, IART has a market cap of 1.3B. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while IART trades at $16.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas IART's P/E ratio is 6.83. In terms of profitability, ZBH's ROE is +0.06%, compared to IART's ROE of -0.01%. Regarding short-term risk, ZBH is less volatile compared to IART. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check IART's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while AVNS trades at $24.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas AVNS's P/E ratio is 27.77. In terms of profitability, ZBH's ROE is +0.06%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, ZBH is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check AVNS's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while SILK trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas SILK's P/E ratio is -18.96. In terms of profitability, ZBH's ROE is +0.06%, compared to SILK's ROE of -0.35%. Regarding short-term risk, ZBH is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check SILK's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, AORT has a market cap of 1.1B. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while AORT trades at $22.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas AORT's P/E ratio is 37.75. In terms of profitability, ZBH's ROE is +0.06%, compared to AORT's ROE of -0.01%. Regarding short-term risk, ZBH is less volatile compared to AORT. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check AORT's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while FNA trades at $13.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas FNA's P/E ratio is -19.83. In terms of profitability, ZBH's ROE is +0.06%, compared to FNA's ROE of -0.35%. Regarding short-term risk, ZBH is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check FNA's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while IRMD trades at $85.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas IRMD's P/E ratio is 43.10. In terms of profitability, ZBH's ROE is +0.06%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, ZBH is more volatile compared to IRMD. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check IRMD's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, TNDM has a market cap of 1.1B. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while TNDM trades at $15.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas TNDM's P/E ratio is -16.90. In terms of profitability, ZBH's ROE is +0.06%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, ZBH is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check TNDM's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, ENOV has a market cap of 1.1B. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while ENOV trades at $18.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas ENOV's P/E ratio is 5.29. In terms of profitability, ZBH's ROE is +0.06%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, ZBH is less volatile compared to ENOV. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check ENOV's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, LMRI has a market cap of 981M. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while LMRI trades at $10.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas LMRI's P/E ratio is -19.86. In terms of profitability, ZBH's ROE is +0.06%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, ZBH is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check LMRI's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, PRCT has a market cap of 979M. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while PRCT trades at $17.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas PRCT's P/E ratio is -8.87. In terms of profitability, ZBH's ROE is +0.06%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, ZBH is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check PRCT's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, BBNX has a market cap of 967.7M. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while BBNX trades at $21.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas BBNX's P/E ratio is -13.04. In terms of profitability, ZBH's ROE is +0.06%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, ZBH is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check BBNX's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, BVS has a market cap of 935.6M. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while BVS trades at $13.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas BVS's P/E ratio is 18.17. In terms of profitability, ZBH's ROE is +0.06%, compared to BVS's ROE of +0.28%. Regarding short-term risk, ZBH is less volatile compared to BVS. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check BVS's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, CBLL has a market cap of 898.9M. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while CBLL trades at $23.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas CBLL's P/E ratio is -13.46. In terms of profitability, ZBH's ROE is +0.06%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, ZBH is more volatile compared to CBLL. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check CBLL's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while CSII trades at $20.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas CSII's P/E ratio is -20.83. In terms of profitability, ZBH's ROE is +0.06%, compared to CSII's ROE of -0.14%. Regarding short-term risk, ZBH is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check CSII's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, SIBN has a market cap of 824.5M. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while SIBN trades at $18.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas SIBN's P/E ratio is -54.68. In terms of profitability, ZBH's ROE is +0.06%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, ZBH is more volatile compared to SIBN. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check SIBN's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, INMD has a market cap of 819.7M. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while INMD trades at $14.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas INMD's P/E ratio is 9.90. In terms of profitability, ZBH's ROE is +0.06%, compared to INMD's ROE of +0.12%. Regarding short-term risk, ZBH is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check INMD's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, VREX has a market cap of 776.7M. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while VREX trades at $18.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas VREX's P/E ratio is 19.42. In terms of profitability, ZBH's ROE is +0.06%, compared to VREX's ROE of +0.05%. Regarding short-term risk, ZBH is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check VREX's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, AHCO has a market cap of 767.3M. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while AHCO trades at $5.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas AHCO's P/E ratio is 11.51. In terms of profitability, ZBH's ROE is +0.06%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, ZBH is more volatile compared to AHCO. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check AHCO's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, AVR has a market cap of 747.7M. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while AVR trades at $7.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas AVR's P/E ratio is -3.96. In terms of profitability, ZBH's ROE is +0.06%, compared to AVR's ROE of -0.78%. Regarding short-term risk, ZBH is less volatile compared to AVR. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check AVR's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, CTKB has a market cap of 729.7M. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while CTKB trades at $5.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas CTKB's P/E ratio is -29.93. In terms of profitability, ZBH's ROE is +0.06%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, ZBH is less volatile compared to CTKB. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check CTKB's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while SRDX trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas SRDX's P/E ratio is -34.66. In terms of profitability, ZBH's ROE is +0.06%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, ZBH is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check SRDX's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, SSII has a market cap of 590.4M. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while SSII trades at $2.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas SSII's P/E ratio is -49.17. In terms of profitability, ZBH's ROE is +0.06%, compared to SSII's ROE of -0.27%. Regarding short-term risk, ZBH is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check SSII's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while APEN trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas APEN's P/E ratio is -9.43. In terms of profitability, ZBH's ROE is +0.06%, compared to APEN's ROE of -0.85%. Regarding short-term risk, ZBH is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check APEN's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, KIDS has a market cap of 579.2M. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while KIDS trades at $22.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas KIDS's P/E ratio is -19.11. In terms of profitability, ZBH's ROE is +0.06%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, ZBH is more volatile compared to KIDS. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check KIDS's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, DCTH has a market cap of 538.5M. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while DCTH trades at $15.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas DCTH's P/E ratio is 1560.00. In terms of profitability, ZBH's ROE is +0.06%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, ZBH is less volatile compared to DCTH. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check DCTH's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while ZIMV trades at $18.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, ZBH's ROE is +0.06%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, ZBH is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check ZIMV's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, CERS has a market cap of 528M. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while CERS trades at $2.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas CERS's P/E ratio is -87.04. In terms of profitability, ZBH's ROE is +0.06%, compared to CERS's ROE of -0.10%. Regarding short-term risk, ZBH is more volatile compared to CERS. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check CERS's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, TCMD has a market cap of 512.7M. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while TCMD trades at $22.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas TCMD's P/E ratio is 21.05. In terms of profitability, ZBH's ROE is +0.06%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, ZBH is more volatile compared to TCMD. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check TCMD's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, PACB has a market cap of 503.2M. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while PACB trades at $1.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas PACB's P/E ratio is -3.95. In terms of profitability, ZBH's ROE is +0.06%, compared to PACB's ROE of -49.62%. Regarding short-term risk, ZBH is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check PACB's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, SGHT has a market cap of 485.9M. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while SGHT trades at $8.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas SGHT's P/E ratio is -15.95. In terms of profitability, ZBH's ROE is +0.06%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, ZBH is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check SGHT's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, NPCE has a market cap of 479.4M. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while NPCE trades at $14.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas NPCE's P/E ratio is -24.67. In terms of profitability, ZBH's ROE is +0.06%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, ZBH is less volatile compared to NPCE. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check NPCE's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, CLPT has a market cap of 444.7M. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while CLPT trades at $14.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas CLPT's P/E ratio is -12.57. In terms of profitability, ZBH's ROE is +0.06%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, ZBH is less volatile compared to CLPT. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check CLPT's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, SENS has a market cap of 417.9M. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while SENS trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas SENS's P/E ratio is -4.48. In terms of profitability, ZBH's ROE is +0.06%, compared to SENS's ROE of -1.66%. Regarding short-term risk, ZBH is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check SENS's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, OFIX has a market cap of 381.6M. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while OFIX trades at $9.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas OFIX's P/E ratio is -6.15. In terms of profitability, ZBH's ROE is +0.06%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, ZBH is less volatile compared to OFIX. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check OFIX's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, CV has a market cap of 332.3M. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while CV trades at $6.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas CV's P/E ratio is -10.56. In terms of profitability, ZBH's ROE is +0.06%, compared to CV's ROE of -1.78%. Regarding short-term risk, ZBH is less volatile compared to CV. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check CV's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while SMLR trades at $20.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas SMLR's P/E ratio is 3.92. In terms of profitability, ZBH's ROE is +0.06%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, ZBH is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check SMLR's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, RCEL has a market cap of 294.1M. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while RCEL trades at $11.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas RCEL's P/E ratio is -8.22. In terms of profitability, ZBH's ROE is +0.06%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, ZBH is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check RCEL's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, TMCI has a market cap of 291.9M. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while TMCI trades at $4.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas TMCI's P/E ratio is -4.79. In terms of profitability, ZBH's ROE is +0.06%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, ZBH is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check TMCI's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, CATX has a market cap of 286.3M. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while CATX trades at $2.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas CATX's P/E ratio is -1.89. In terms of profitability, ZBH's ROE is +0.06%, compared to CATX's ROE of -0.42%. Regarding short-term risk, ZBH is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check CATX's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, TLSI has a market cap of 267.2M. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while TLSI trades at $4.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas TLSI's P/E ratio is -2.58. In terms of profitability, ZBH's ROE is +0.06%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, ZBH is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check TLSI's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, INFU has a market cap of 257.3M. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while INFU trades at $12.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas INFU's P/E ratio is 31.10. In terms of profitability, ZBH's ROE is +0.06%, compared to INFU's ROE of +0.15%. Regarding short-term risk, ZBH is more volatile compared to INFU. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check INFU's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while MGRM trades at $6.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas MGRM's P/E ratio is -12.00. In terms of profitability, ZBH's ROE is +0.06%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, ZBH is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check MGRM's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, ELMD has a market cap of 231.4M. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while ELMD trades at $27.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas ELMD's P/E ratio is 21.34. In terms of profitability, ZBH's ROE is +0.06%, compared to ELMD's ROE of +0.23%. Regarding short-term risk, ZBH is more volatile compared to ELMD. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check ELMD's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while NVRO trades at $5.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas NVRO's P/E ratio is -1.91. In terms of profitability, ZBH's ROE is +0.06%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, ZBH is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check NVRO's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, PROF has a market cap of 209.3M. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while PROF trades at $5.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas PROF's P/E ratio is -5.88. In terms of profitability, ZBH's ROE is +0.06%, compared to PROF's ROE of -0.56%. Regarding short-term risk, ZBH is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check PROF's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, RXST has a market cap of 192.9M. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while RXST trades at $4.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas RXST's P/E ratio is -4.12. In terms of profitability, ZBH's ROE is +0.06%, compared to RXST's ROE of -0.17%. Regarding short-term risk, ZBH is less volatile compared to RXST. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check RXST's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while BSGM trades at $6.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas BSGM's P/E ratio is -5.81. In terms of profitability, ZBH's ROE is +0.06%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, ZBH is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check BSGM's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, STIM has a market cap of 190.7M. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while STIM trades at $2.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas STIM's P/E ratio is -6.23. In terms of profitability, ZBH's ROE is +0.06%, compared to STIM's ROE of -1.51%. Regarding short-term risk, ZBH is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check STIM's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while MDGS trades at $2.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas MDGS's P/E ratio is -0.27. In terms of profitability, ZBH's ROE is +0.06%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, ZBH is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check MDGS's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, FOCL has a market cap of 176.5M. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while FOCL trades at $4.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas FOCL's P/E ratio is -4.55. In terms of profitability, ZBH's ROE is +0.06%, compared to FOCL's ROE of -2.90%. Regarding short-term risk, ZBH is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check FOCL's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, QSI has a market cap of 165M. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while QSI trades at $0.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas QSI's P/E ratio is -1.81. In terms of profitability, ZBH's ROE is +0.06%, compared to QSI's ROE of -0.47%. Regarding short-term risk, ZBH is less volatile compared to QSI. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check QSI's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while QIPT trades at $3.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas QIPT's P/E ratio is -15.87. In terms of profitability, ZBH's ROE is +0.06%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, ZBH is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check QIPT's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, LUCD has a market cap of 157.6M. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while LUCD trades at $0.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas LUCD's P/E ratio is -2.23. In terms of profitability, ZBH's ROE is +0.06%, compared to LUCD's ROE of -4.04%. Regarding short-term risk, ZBH is less volatile compared to LUCD. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check LUCD's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, QTRX has a market cap of 154M. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while QTRX trades at $3.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas QTRX's P/E ratio is -1.29. In terms of profitability, ZBH's ROE is +0.06%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, ZBH is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check QTRX's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, INGN has a market cap of 145.1M. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while INGN trades at $5.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas INGN's P/E ratio is -5.89. In terms of profitability, ZBH's ROE is +0.06%, compared to INGN's ROE of -0.13%. Regarding short-term risk, ZBH is less volatile compared to INGN. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check INGN's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while ICAD trades at $3.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas ICAD's P/E ratio is -20.37. In terms of profitability, ZBH's ROE is +0.06%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, ZBH is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check ICAD's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, ECOR has a market cap of 100.3M. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while ECOR trades at $11.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas ECOR's P/E ratio is -6.62. In terms of profitability, ZBH's ROE is +0.06%, compared to ECOR's ROE of +5.25%. Regarding short-term risk, ZBH is less volatile compared to ECOR. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check ECOR's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while HJLI trades at $10.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas HJLI's P/E ratio is N/A. In terms of profitability, ZBH's ROE is +0.06%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, ZBH is less volatile compared to HJLI. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check HJLI's competition here

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZBH stands at 17.6B. In comparison, ASXC has a market cap of 94.9M. Regarding current trading prices, ZBH is priced at $91.04 on the NYSE, while ASXC trades at $0.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZBH currently has a P/E ratio of 10.73, whereas ASXC's P/E ratio is -1.12. In terms of profitability, ZBH's ROE is +0.06%, compared to ASXC's ROE of -1.18%. Regarding short-term risk, ZBH is more volatile compared to ASXC. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check ASXC's competition here